Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ivabradine · 1 trial · 1 indication
Orthostatic heart rate monitoring will be used to gauge heart rate changes.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Patient will consume one placebo pill twice a day for one month. |
| Ivabradine | EXPERIMENTAL | Patient will consume one dose of Ivabradine twice a day for one month. |
| Name | Type | Description |
|---|---|---|
| Ivabradine | DRUG | Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node. |
| Placebo | DRUG | A substance that has no therapeutic effect and will act as a control. |
Inclusion Criteria: * Subjects aged 18-65. * Subjects must have POTS diagnosis (Hyperadrenergic Subtype with NE\> 600pg/ml)) * Subjects with no structural heart disease * Subject with no arrhythmias * Subjects with norepinephrine levels greater than 600 pg/ml * Subjects with normal CBC, Metabolic, ...
Ivabradine is a small molecule being studied for the treatment of Postural Orthostatic Tachycardia Syndrome (POTS). It is currently in Phase 3 clinical development and is investigational, meaning it has not been approved for this condition. The drug is being developed by Amgen Inc. (NASDAQ: AMGN).
Ivabradine works by targeting the If current in the sinoatrial node, which helps regulate heart rate. By inhibiting this current, Ivabradine can reduce heart rate without affecting blood pressure. This mechanism is being evaluated in patients with Postural Orthostatic Tachycardia Syndrome to potentially manage symptoms related to excessive heart rate.
Ivabradine is being developed by Amgen Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol AMGN. The company is conducting clinical trials to evaluate the drug's safety and efficacy for Postural Orthostatic Tachycardia Syndrome.
Ivabradine is in Phase 3 clinical development for Postural Orthostatic Tachycardia Syndrome. It is an investigational drug, meaning it has not yet received regulatory approval. The Phase 3 trial has been completed, with results expected to inform potential future regulatory submissions.
Ivabradine has one completed Phase 3 clinical trial registered under NCT03182725, titled 'Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome.' This randomized, double-blind, placebo-controlled study enrolled 37 participants in the United States and included biomarker selection.
Ivabradine is the active ingredient in the brand-name drug Corlanor, which is approved for other cardiovascular conditions. However, for Postural Orthostatic Tachycardia Syndrome, Ivabradine is being investigated as an investigational therapy and is not yet approved for this specific indication.